Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA co-administered with PCV20 in older adults
NCT05879107Phase 3Completed
- Sponsor
- GSK
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (2 arms), sponsored by GSK. Primary endpoints: Adjusted Geometric Mean Titers of Opsonophagocytic Titers at Day 31, Adjusted Geometric Mean Titers of RSV-A Neutralizing Titers at Day 61 and 1 more. Started May 2023; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05879107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879107.